Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413171 | 0.84 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5418094 | 0.84 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5425273 | 0.83 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL24373738 | 0.81 | CYP4F2 (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL21198237 | 0.81 | ALDH1A1 (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5417592 | 0.81 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5407927 | 0.81 | RXRA (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5409247 | 0.81 | RXRA (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5412256 | 0.81 | RXRA (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5419556 | 0.81 | RXRA (0.39) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | RXRA 1096/4885RXRB 1324/4885RXRG 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.